159 related articles for article (PubMed ID: 14757777)
1. AT1 receptor blocker added to ACE inhibitor provides benefits at advanced stage of hypertensive diastolic heart failure.
Yoshida J; Yamamoto K; Mano T; Sakata Y; Nishikawa N; Nishio M; Ohtani T; Miwa T; Hori M; Masuyama T
Hypertension; 2004 Mar; 43(3):686-91. PubMed ID: 14757777
[TBL] [Abstract][Full Text] [Related]
2. ACE inhibitor and angiotensin II type 1 receptor blocker differently regulate ventricular fibrosis in hypertensive diastolic heart failure.
Yamamoto K; Mano T; Yoshida J; Sakata Y; Nishikawa N; Nishio M; Ohtani T; Hori M; Miwa T; Masuyama T
J Hypertens; 2005 Feb; 23(2):393-400. PubMed ID: 15662228
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic effects of angiotensin II type 1 receptor blocker at an advanced stage of hypertensive diastolic heart failure.
Nishio M; Sakata Y; Mano T; Yoshida J; Ohtani T; Takeda Y; Miwa T; Masuyama T; Yamamoto K; Hori M
J Hypertens; 2007 Feb; 25(2):455-61. PubMed ID: 17211254
[TBL] [Abstract][Full Text] [Related]
4. Additive beneficial effects of the combination of a calcium channel blocker and an angiotensin blocker on a hypertensive rat-heart failure model.
Kim-Mitsuyama S; Izumi Y; Izumiya Y; Yoshida K; Yoshiyama M; Iwao H
Hypertens Res; 2004 Oct; 27(10):771-9. PubMed ID: 15785013
[TBL] [Abstract][Full Text] [Related]
5. Temocapril prevents transition to diastolic heart failure in rats even if initiated after appearance of LV hypertrophy and diastolic dysfunction.
Sakata Y; Yamamoto K; Mano T; Nishikawa N; Yoshida J; Miwa T; Hori M; Masuyama T
Cardiovasc Res; 2003 Mar; 57(3):757-65. PubMed ID: 12618237
[TBL] [Abstract][Full Text] [Related]
6. Should increasing the dose or adding an AT1 receptor blocker follow a relatively low dose of ACE inhibitor initiated in acute myocardial infarction?
Sugie T; Kagaya Y; Takeda M; Yahagi H; Takahashi C; Takahashi J; Ninomiya M; Watanabe J; Ichinohasama R; Tezuka F; Shirato K
Cardiovasc Res; 2003 Jun; 58(3):611-20. PubMed ID: 12798434
[TBL] [Abstract][Full Text] [Related]
7. Beneficial effects of combination of ACE inhibitor and angiotensin II type 1 receptor blocker on cardiac remodeling in rat myocardial infarction.
Nakamura Y; Yoshiyama M; Omura T; Yoshida K; Izumi Y; Takeuchi K; Kim S; Iwao H; Yoshikawa J
Cardiovasc Res; 2003 Jan; 57(1):48-54. PubMed ID: 12504813
[TBL] [Abstract][Full Text] [Related]
8. Beneficial effects of angiotensin-converting enzyme inhibition on sarcoplasmic reticulum function in the failing heart of the Dahl rat.
Satoh S; Ueda Y; Suematsu N; Oyama J; Kadokami T; Sugano M; Yoshikawa Y; Makino N
Circ J; 2003 Aug; 67(8):705-11. PubMed ID: 12890915
[TBL] [Abstract][Full Text] [Related]
9. Angiotensin II type 1 receptor blockade prevents diastolic heart failure through modulation of Ca(2+) regulatory proteins and extracellular matrix.
Sakata Y; Yamamoto K; Mano T; Nishikawa N; Yoshida J; Nakayama H; Otsu K; Suzuki K; Tada M; Hori M; Miwa T; Masuyama T
J Hypertens; 2003 Sep; 21(9):1737-45. PubMed ID: 12923407
[TBL] [Abstract][Full Text] [Related]
10. Angiotensin receptor antagonism and angiotensin converting enzyme inhibition improve diastolic dysfunction and Ca(2+)-ATPase expression in the sarcoplasmic reticulum in hypertensive cardiomyopathy.
Flesch M; Schiffer F; Zolk O; Pinto Y; Stasch JP; Knorr A; Ettelbrück S; Böhm M
J Hypertens; 1997 Sep; 15(9):1001-9. PubMed ID: 9321748
[TBL] [Abstract][Full Text] [Related]
11. Contribution of reactive oxygen species to the pathogenesis of left ventricular failure in Dahl salt-sensitive hypertensive rats: effects of angiotensin II blockade.
Guo P; Nishiyama A; Rahman M; Nagai Y; Noma T; Namba T; Ishizawa M; Murakami K; Miyatake A; Kimura S; Mizushige K; Abe Y; Ohmori K; Kohno M
J Hypertens; 2006 Jun; 24(6):1097-104. PubMed ID: 16685210
[TBL] [Abstract][Full Text] [Related]
12. A newly developed angiotensin II type 1 receptor antagonist, CS866, promotes regression of cardiac hypertrophy by reducing integrin beta1 expression.
Jia N; Okamoto H; Shimizu T; Chiba S; Matsui Y; Sugawara T; Akino M; Kitabatake A
Hypertens Res; 2003 Sep; 26(9):737-42. PubMed ID: 14620930
[TBL] [Abstract][Full Text] [Related]
13. Beneficial effects of olmesartan and temocapril on urinary liver-type fatty acid-binding protein levels in normotensive patients with immunoglobin A nephropathy.
Nakamura T; Inoue T; Sugaya T; Kawagoe Y; Suzuki T; Ueda Y; Koide H; Node K
Am J Hypertens; 2007 Nov; 20(11):1195-201. PubMed ID: 17954367
[TBL] [Abstract][Full Text] [Related]
14. Effects of combination of ACE inhibitor and angiotensin receptor blocker on cardiac remodeling, cardiac function, and survival in rat heart failure.
Kim S; Yoshiyama M; Izumi Y; Kawano H; Kimoto M; Zhan Y; Iwao H
Circulation; 2001 Jan; 103(1):148-54. PubMed ID: 11136700
[TBL] [Abstract][Full Text] [Related]
15. Salutary effects of attenuation of angiotensin II on coronary perivascular fibrosis associated with insulin resistance and obesity.
Zaman AK; Fujii S; Goto D; Furumoto T; Mishima T; Nakai Y; Dong J; Imagawa S; Sobel BE; Kitabatake A
J Mol Cell Cardiol; 2004 Aug; 37(2):525-35. PubMed ID: 15276022
[TBL] [Abstract][Full Text] [Related]
16. Left ventricular wall stress and sarcoplasmic reticulum Ca(2+)-ATPase gene expression in renal hypertensive rats: dose-dependent effects of ACE inhibition and AT1-receptor blockade.
Zierhut W; Studer R; Laurent D; Kästner S; Allegrini P; Whitebread S; Cumin F; Baum HP; de Gasparo M; Drexler H
Cardiovasc Res; 1996 May; 31(5):758-68. PubMed ID: 8763405
[TBL] [Abstract][Full Text] [Related]
17. Effects of monotherapy of temocapril or candesartan with dose increments or combination therapy with both drugs on the suppression of diabetic nephropathy.
Ogawa S; Takeuchi K; Mori T; Nako K; Tsubono Y; Ito S
Hypertens Res; 2007 Apr; 30(4):325-34. PubMed ID: 17541211
[TBL] [Abstract][Full Text] [Related]
18. Clinical impacts of additive use of olmesartan in hypertensive patients with chronic heart failure: the supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial.
Sakata Y; Shiba N; Takahashi J; Miyata S; Nochioka K; Miura M; Takada T; Saga C; Shinozaki T; Sugi M; Nakagawa M; Sekiguchi N; Komaru T; Kato A; Fukuchi M; Nozaki E; Hiramoto T; Inoue K; Goto T; Ohe M; Tamaki K; Ibayashi S; Ishide N; Maruyama Y; Tsuji I; Shimokawa H; ;
Eur Heart J; 2015 Apr; 36(15):915-23. PubMed ID: 25637937
[TBL] [Abstract][Full Text] [Related]
19. Combined angiotensin receptor blocker and ACE inhibitor on myocardial fibrosis and left ventricular stiffness in dogs with heart failure.
Funabiki K; Onishi K; Dohi K; Koji T; Imanaka-Yoshida K; Ito M; Wada H; Isaka N; Nobori T; Nakano T
Am J Physiol Heart Circ Physiol; 2004 Dec; 287(6):H2487-92. PubMed ID: 15548724
[TBL] [Abstract][Full Text] [Related]
20. Beta-blocker improves survival, left ventricular function, and myocardial remodeling in hypertensive rats with diastolic heart failure.
Kobayashi M; Machida N; Mitsuishi M; Yamane Y
Am J Hypertens; 2004 Dec; 17(12 Pt 1):1112-9. PubMed ID: 15607617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
